ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.630
-0.040 (-2.40%)
Feb 21, 2025, 4:00 PM EST - Market closed
ADC Therapeutics Revenue
ADC Therapeutics had revenue of $18.46M in the quarter ending September 30, 2024, with 27.40% growth. This brings the company's revenue in the last twelve months to $70.72M, down -42.30% year-over-year. In the year 2023, ADC Therapeutics had annual revenue of $69.56M, down -66.86%.
Revenue (ttm)
$70.72M
Revenue Growth
-42.30%
P/S Ratio
2.11
Revenue / Employee
$258,091
Employees
274
Market Cap
157.60M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ADCT News
- 18 days ago - ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PRNewsWire
- 23 days ago - ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - PRNewsWire
- 7 weeks ago - ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PRNewsWire
- 2 months ago - ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL - Seeking Alpha
- 2 months ago - ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - PRNewsWire
- 2 months ago - ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - PRNewsWire
- 2 months ago - ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial - PRNewsWire
- 3 months ago - ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript - Seeking Alpha